1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hematological Cancers Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Pharmacological Therapies 1.2.3 Stem Cell Transplantation 1.2.4 Surgery and Radiation Therapy 1.2.5 Anemia Treatment 1.2.6 Thrombosis Treatment 1.2.7 Neutopenia Treatment 1.2.8 Symptomatic treatment 1.3 Market by Application 1.3.1 Global Hematological Cancers Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Epidemiology 1.3.3 Pathophysiology of Leukemic Stem Cells 1.3.4 Kidney Diseases 1.3.5 Genetic Diseases 1.3.6 Other Diseases 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Hematological Cancers Market Perspective (2016-2027) 2.2 Hematological Cancers Growth Trends by Regions 2.2.1 Hematological Cancers Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Hematological Cancers Historic Market Share by Regions (2016-2021) 2.2.3 Hematological Cancers Forecasted Market Size by Regions (2022-2027) 2.3 Hematological Cancers Industry Dynamic 2.3.1 Hematological Cancers Market Trends 2.3.2 Hematological Cancers Market Drivers 2.3.3 Hematological Cancers Market Challenges 2.3.4 Hematological Cancers Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hematological Cancers Players by Revenue 3.1.1 Global Top Hematological Cancers Players by Revenue (2016-2021) 3.1.2 Global Hematological Cancers Revenue Market Share by Players (2016-2021) 3.2 Global Hematological Cancers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Hematological Cancers Revenue 3.4 Global Hematological Cancers Market Concentration Ratio 3.4.1 Global Hematological Cancers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hematological Cancers Revenue in 2020 3.5 Hematological Cancers Key Players Head office and Area Served 3.6 Key Players Hematological Cancers Product Solution and Service 3.7 Date of Enter into Hematological Cancers Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hematological Cancers Breakdown Data by Type 4.1 Global Hematological Cancers Historic Market Size by Type (2016-2021) 4.2 Global Hematological Cancers Forecasted Market Size by Type (2022-2027) 5 Hematological Cancers Breakdown Data by Application 5.1 Global Hematological Cancers Historic Market Size by Application (2016-2021) 5.2 Global Hematological Cancers Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Hematological Cancers Market Size (2016-2027) 6.2 North America Hematological Cancers Market Size by Type 6.2.1 North America Hematological Cancers Market Size by Type (2016-2021) 6.2.2 North America Hematological Cancers Market Size by Type (2022-2027) 6.2.3 North America Hematological Cancers Market Size by Type (2016-2027) 6.3 North America Hematological Cancers Market Size by Application 6.3.1 North America Hematological Cancers Market Size by Application (2016-2021) 6.3.2 North America Hematological Cancers Market Size by Application (2022-2027) 6.3.3 North America Hematological Cancers Market Size by Application (2016-2027) 6.4 North America Hematological Cancers Market Size by Country 6.4.1 North America Hematological Cancers Market Size by Country (2016-2021) 6.4.2 North America Hematological Cancers Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Hematological Cancers Market Size (2016-2027) 7.2 Europe Hematological Cancers Market Size by Type 7.2.1 Europe Hematological Cancers Market Size by Type (2016-2021) 7.2.2 Europe Hematological Cancers Market Size by Type (2022-2027) 7.2.3 Europe Hematological Cancers Market Size by Type (2016-2027) 7.3 Europe Hematological Cancers Market Size by Application 7.3.1 Europe Hematological Cancers Market Size by Application (2016-2021) 7.3.2 Europe Hematological Cancers Market Size by Application (2022-2027) 7.3.3 Europe Hematological Cancers Market Size by Application (2016-2027) 7.4 Europe Hematological Cancers Market Size by Country 7.4.1 Europe Hematological Cancers Market Size by Country (2016-2021) 7.4.2 Europe Hematological Cancers Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Hematological Cancers Market Size (2016-2027) 8.2 Asia-Pacific Hematological Cancers Market Size by Type 8.2.1 Asia-Pacific Hematological Cancers Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Hematological Cancers Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Hematological Cancers Market Size by Type (2016-2027) 8.3 Asia-Pacific Hematological Cancers Market Size by Application 8.3.1 Asia-Pacific Hematological Cancers Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Hematological Cancers Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Hematological Cancers Market Size by Application (2016-2027) 8.4 Asia-Pacific Hematological Cancers Market Size by Region 8.4.1 Asia-Pacific Hematological Cancers Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Hematological Cancers Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Hematological Cancers Market Size (2016-2027) 9.2 Latin America Hematological Cancers Market Size by Type 9.2.1 Latin America Hematological Cancers Market Size by Type (2016-2021) 9.2.2 Latin America Hematological Cancers Market Size by Type (2022-2027) 9.2.3 Latin America Hematological Cancers Market Size by Type (2016-2027) 9.3 Latin America Hematological Cancers Market Size by Application 9.3.1 Latin America Hematological Cancers Market Size by Application (2016-2021) 9.3.2 Latin America Hematological Cancers Market Size by Application (2022-2027) 9.3.3 Latin America Hematological Cancers Market Size by Application (2016-2027) 9.4 Latin America Hematological Cancers Market Size by Country 9.4.1 Latin America Hematological Cancers Market Size by Country (2016-2021) 9.4.2 Latin America Hematological Cancers Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Hematological Cancers Market Size (2016-2027) 10.2 Middle East & Africa Hematological Cancers Market Size by Type 10.2.1 Middle East & Africa Hematological Cancers Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Hematological Cancers Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Hematological Cancers Market Size by Type (2016-2027) 10.3 Middle East & Africa Hematological Cancers Market Size by Application 10.3.1 Middle East & Africa Hematological Cancers Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Hematological Cancers Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Hematological Cancers Market Size by Application (2016-2027) 10.4 Middle East & Africa Hematological Cancers Market Size by Country 10.4.1 Middle East & Africa Hematological Cancers Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Hematological Cancers Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Karyopharm Therapeutics 11.1.1 Karyopharm Therapeutics Company Details 11.1.2 Karyopharm Therapeutics Business Overview 11.1.3 Karyopharm Therapeutics Hematological Cancers Introduction 11.1.4 Karyopharm Therapeutics Revenue in Hematological Cancers Business (2016-2021) 11.1.5 Karyopharm Therapeutics Recent Development 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Details 11.2.2 Johnson & Johnson Business Overview 11.2.3 Johnson & Johnson Hematological Cancers Introduction 11.2.4 Johnson & Johnson Revenue in Hematological Cancers Business (2016-2021) 11.2.5 Johnson & Johnson Recent Development 11.3 Roche Diagnostics A/S 11.3.1 Roche Diagnostics A/S Company Details 11.3.2 Roche Diagnostics A/S Business Overview 11.3.3 Roche Diagnostics A/S Hematological Cancers Introduction 11.3.4 Roche Diagnostics A/S Revenue in Hematological Cancers Business (2016-2021) 11.3.5 Roche Diagnostics A/S Recent Development 11.4 AbbVie 11.4.1 AbbVie Company Details 11.4.2 AbbVie Business Overview 11.4.3 AbbVie Hematological Cancers Introduction 11.4.4 AbbVie Revenue in Hematological Cancers Business (2016-2021) 11.4.5 AbbVie Recent Development 11.5 Novartis 11.5.1 Novartis Company Details 11.5.2 Novartis Business Overview 11.5.3 Novartis Hematological Cancers Introduction 11.5.4 Novartis Revenue in Hematological Cancers Business (2016-2021) 11.5.5 Novartis Recent Development 11.6 Kite Pharma 11.6.1 Kite Pharma Company Details 11.6.2 Kite Pharma Business Overview 11.6.3 Kite Pharma Hematological Cancers Introduction 11.6.4 Kite Pharma Revenue in Hematological Cancers Business (2016-2021) 11.6.5 Kite Pharma Recent Development 11.7 Celgene Corporation 11.7.1 Celgene Corporation Company Details 11.7.2 Celgene Corporation Business Overview 11.7.3 Celgene Corporation Hematological Cancers Introduction 11.7.4 Celgene Corporation Revenue in Hematological Cancers Business (2016-2021) 11.7.5 Celgene Corporation Recent Development 11.8 Abbott Laboratories 11.8.1 Abbott Laboratories Company Details 11.8.2 Abbott Laboratories Business Overview 11.8.3 Abbott Laboratories Hematological Cancers Introduction 11.8.4 Abbott Laboratories Revenue in Hematological Cancers Business (2016-2021) 11.8.5 Abbott Laboratories Recent Development 11.9 Beckman Coulter 11.9.1 Beckman Coulter Company Details 11.9.2 Beckman Coulter Business Overview 11.9.3 Beckman Coulter Hematological Cancers Introduction 11.9.4 Beckman Coulter Revenue in Hematological Cancers Business (2016-2021) 11.9.5 Beckman Coulter Recent Development 11.10 HemoCue AB 11.10.1 HemoCue AB Company Details 11.10.2 HemoCue AB Business Overview 11.10.3 HemoCue AB Hematological Cancers Introduction 11.10.4 HemoCue AB Revenue in Hematological Cancers Business (2016-2021) 11.10.5 HemoCue AB Recent Development 11.11 C. R. Bard 11.11.1 C. R. Bard Company Details 11.11.2 C. R. Bard Business Overview 11.11.3 C. R. Bard Hematological Cancers Introduction 11.11.4 C. R. Bard Revenue in Hematological Cancers Business (2016-2021) 11.11.5 C. R. Bard Recent Development 11.12 Siemens AG 11.12.1 Siemens AG Company Details 11.12.2 Siemens AG Business Overview 11.12.3 Siemens AG Hematological Cancers Introduction 11.12.4 Siemens AG Revenue in Hematological Cancers Business (2016-2021) 11.12.5 Siemens AG Recent Development 11.13 Sysmex 11.13.1 Sysmex Company Details 11.13.2 Sysmex Business Overview 11.13.3 Sysmex Hematological Cancers Introduction 11.13.4 Sysmex Revenue in Hematological Cancers Business (2016-2021) 11.13.5 Sysmex Recent Development 11.14 Mindray Medical International Limited 11.14.1 Mindray Medical International Limited Company Details 11.14.2 Mindray Medical International Limited Business Overview 11.14.3 Mindray Medical International Limited Hematological Cancers Introduction 11.14.4 Mindray Medical International Limited Revenue in Hematological Cancers Business (2016-2021) 11.14.5 Mindray Medical International Limited Recent Development 11.15 Bio-Rad Laboratories 11.15.1 Bio-Rad Laboratories Company Details 11.15.2 Bio-Rad Laboratories Business Overview 11.15.3 Bio-Rad Laboratories Hematological Cancers Introduction 11.15.4 Bio-Rad Laboratories Revenue in Hematological Cancers Business (2016-2021) 11.15.5 Bio-Rad Laboratories Recent Development 11.16 The Medicine Company 11.16.1 The Medicine Company Company Details 11.16.2 The Medicine Company Business Overview 11.16.3 The Medicine Company Hematological Cancers Introduction 11.16.4 The Medicine Company Revenue in Hematological Cancers Business (2016-2021) 11.16.5 The Medicine Company Recent Development 11.17 Pharmacyclics 11.17.1 Pharmacyclics Company Details 11.17.2 Pharmacyclics Business Overview 11.17.3 Pharmacyclics Hematological Cancers Introduction 11.17.4 Pharmacyclics Revenue in Hematological Cancers Business (2016-2021) 11.17.5 Pharmacyclics Recent Development 11.18 Horiba 11.18.1 Horiba Company Details 11.18.2 Horiba Business Overview 11.18.3 Horiba Hematological Cancers Introduction 11.18.4 Horiba Revenue in Hematological Cancers Business (2016-2021) 11.18.5 Horiba Recent Development 11.19 DiagnoCure Inc. 11.19.1 DiagnoCure Inc. Company Details 11.19.2 DiagnoCure Inc. Business Overview 11.19.3 DiagnoCure Inc. Hematological Cancers Introduction 11.19.4 DiagnoCure Inc. Revenue in Hematological Cancers Business (2016-2021) 11.19.5 DiagnoCure Inc. Recent Development 11.20 Astellas Pharma US 11.20.1 Astellas Pharma US Company Details 11.20.2 Astellas Pharma US Business Overview 11.20.3 Astellas Pharma US Hematological Cancers Introduction 11.20.4 Astellas Pharma US Revenue in Hematological Cancers Business (2016-2021) 11.20.5 Astellas Pharma US Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hematological Cancers Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Pharmacological Therapies Table 3. Key Players of Stem Cell Transplantation Table 4. Key Players of Surgery and Radiation Therapy Table 5. Key Players of Anemia Treatment Table 6. Key Players of Thrombosis Treatment Table 7. Key Players of Neutopenia Treatment Table 8. Key Players of Symptomatic treatment Table 9. Global Hematological Cancers Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Hematological Cancers Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 11. Global Hematological Cancers Market Size by Regions (2016-2021) & (US$ Million) Table 12. Global Hematological Cancers Market Share by Regions (2016-2021) Table 13. Global Hematological Cancers Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 14. Global Hematological Cancers Market Share by Regions (2022-2027) Table 15. Hematological Cancers Market Trends Table 16. Hematological Cancers Market Drivers Table 17. Hematological Cancers Market Challenges Table 18. Hematological Cancers Market Restraints Table 19. Global Hematological Cancers Revenue by Players (2016-2021) & (US$ Million) Table 20. Global Hematological Cancers Market Share by Players (2016-2021) Table 21. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Cancers as of 2020) Table 22. Ranking of Global Top Hematological Cancers Companies by Revenue (US$ Million) in 2020 Table 23. Global 5 Largest Players Market Share by Hematological Cancers Revenue (CR5 and HHI) & (2016-2021) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Hematological Cancers Product Solution and Service Table 26. Date of Enter into Hematological Cancers Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 29. Global Hematological Cancers Revenue Market Share by Type (2016-2021) Table 30. Global Hematological Cancers Forecasted Market Size by Type (2022-2027) (US$ Million) Table 31. Global Hematological Cancers Revenue Market Share by Type (2022-2027) & (US$ Million) Table 32. Global Hematological Cancers Market Size Share by Application (2016-2021) & (US$ Million) Table 33. Global Hematological Cancers Revenue Market Share by Application (2016-2021) Table 34. Global Hematological Cancers Forecasted Market Size by Application (2022-2027) (US$ Million) Table 35. Global Hematological Cancers Revenue Market Share by Application (2022-2027) & (US$ Million) Table 36. North America Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 37. North America Hematological Cancers Market Size by Type (2022-2027) & (US$ Million) Table 38. North America Hematological Cancers Market Size by Application (2016-2021) (US$ Million) Table 39. North America Hematological Cancers Market Size by Application (2022-2027) & (US$ Million) Table 40. North America Hematological Cancers Market Size by Country (2016-2021) & (US$ Million) Table 41. North America Hematological Cancers Market Size by Country (2022-2027) & (US$ Million) Table 42. Europe Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 43. Europe Hematological Cancers Market Size by Type (2022-2027) & (US$ Million) Table 44. Europe Hematological Cancers Market Size by Application (2016-2021) (US$ Million) Table 45. Europe Hematological Cancers Market Size by Application (2022-2027) & (US$ Million) Table 46. Europe Hematological Cancers Market Size by Country (2016-2021) & (US$ Million) Table 47. Europe Hematological Cancers Market Size by Country (2022-2027) & (US$ Million) Table 48. Asia-Pacific Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 49. Asia-Pacific Hematological Cancers Market Size by Type (2022-2027) & (US$ Million) Table 50. Asia-Pacific Hematological Cancers Market Size by Application (2016-2021) (US$ Million) Table 51. Asia-Pacific Hematological Cancers Market Size by Application (2022-2027) & (US$ Million) Table 52. Asia-Pacific Hematological Cancers Market Size by Region (2016-2021) & (US$ Million) Table 53. Asia-Pacific Hematological Cancers Market Size by Region (2022-2027) & (US$ Million) Table 54. Latin America Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 55. Latin America Hematological Cancers Market Size by Type (2022-2027) & (US$ Million) Table 56. Latin America Hematological Cancers Market Size by Application (2016-2021) (US$ Million) Table 57. Latin America Hematological Cancers Market Size by Application (2022-2027) & (US$ Million) Table 58. Latin America Hematological Cancers Market Size by Country (2016-2021) & (US$ Million) Table 59. Latin America Hematological Cancers Market Size by Country (2022-2027) & (US$ Million) Table 60. Middle East & Africa Hematological Cancers Market Size by Type (2016-2021) (US$ Million) Table 61. Middle East & Africa Hematological Cancers Market Size by Type (2022-2027) & (US$ Million) Table 62. Middle East & Africa Hematological Cancers Market Size by Application (2016-2021) (US$ Million) Table 63. Middle East & Africa Hematological Cancers Market Size by Application (2022-2027) & (US$ Million) Table 64. Middle East & Africa Hematological Cancers Market Size by Country (2016-2021) & (US$ Million) Table 65. Middle East & Africa Hematological Cancers Market Size by Country (2022-2027) & (US$ Million) Table 66. Karyopharm Therapeutics Company Details Table 67. Karyopharm Therapeutics Business Overview Table 68. Karyopharm Therapeutics Hematological Cancers Product Table 69. Karyopharm Therapeutics Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 70. Karyopharm Therapeutics Recent Development Table 71. Johnson & Johnson Company Details Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Hematological Cancers Product Table 74. Johnson & Johnson Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 75. Johnson & Johnson Recent Development Table 76. Roche Diagnostics A/S Company Details Table 77. Roche Diagnostics A/S Business Overview Table 78. Roche Diagnostics A/S Hematological Cancers Product Table 79. Roche Diagnostics A/S Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 80. Roche Diagnostics A/S Recent Development Table 81. AbbVie Company Details Table 82. AbbVie Business Overview Table 83. AbbVie Hematological Cancers Product Table 84. AbbVie Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 85. AbbVie Recent Development Table 86. Novartis Company Details Table 87. Novartis Business Overview Table 88. Novartis Hematological Cancers Product Table 89. Novartis Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 90. Novartis Recent Development Table 91. Kite Pharma Company Details Table 92. Kite Pharma Business Overview Table 93. Kite Pharma Hematological Cancers Product Table 94. Kite Pharma Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 95. Kite Pharma Recent Development Table 96. Celgene Corporation Company Details Table 97. Celgene Corporation Business Overview Table 98. Celgene Corporation Hematological Cancers Product Table 99. Celgene Corporation Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 100. Celgene Corporation Recent Development Table 101. Abbott Laboratories Company Details Table 102. Abbott Laboratories Business Overview Table 103. Abbott Laboratories Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 104. Abbott Laboratories Recent Development Table 105. Beckman Coulter Company Details Table 106. Beckman Coulter Business Overview Table 107. Beckman Coulter Hematological Cancers Product Table 108. Beckman Coulter Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 109. Beckman Coulter Recent Development Table 110. HemoCue AB Company Details Table 111. HemoCue AB Business Overview Table 112. HemoCue AB Hematological Cancers Product Table 113. HemoCue AB Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 114. HemoCue AB Recent Development Table 115. C. R. Bard Company Details Table 116. C. R. Bard Business Overview Table 117. C. R. Bard Hematological Cancers Product Table 118. C. R. Bard Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 119. C. R. Bard Recent Development Table 120. Siemens AG Company Details Table 121. Siemens AG Business Overview Table 122. Siemens AG Hematological Cancers Product Table 123. Siemens AG Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 124. Siemens AG Recent Development Table 125. Sysmex Company Details Table 126. Sysmex Business Overview Table 127. Sysmex Hematological Cancers Product Table 128. Sysmex Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 129. Sysmex Recent Development Table 130. Mindray Medical International Limited Company Details Table 131. Mindray Medical International Limited Business Overview Table 132. Mindray Medical International Limited Hematological Cancers Product Table 133. Mindray Medical International Limited Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 134. Mindray Medical International Limited Recent Development Table 135. Bio-Rad Laboratories Company Details Table 136. Bio-Rad Laboratories Business Overview Table 137. Bio-Rad Laboratories Hematological Cancers Product Table 138. Bio-Rad Laboratories Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 139. Bio-Rad Laboratories Recent Development Table 140. The Medicine Company Company Details Table 141. The Medicine Company Business Overview Table 142. The Medicine Company Hematological Cancers Product Table 143. The Medicine Company Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 144. The Medicine Company Recent Development Table 145. Pharmacyclics Company Details Table 146. Pharmacyclics Business Overview Table 147. Pharmacyclics Hematological Cancers Product Table 148. Pharmacyclics Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 149. Pharmacyclics Recent Development Table 150. Horiba Company Details Table 151. Horiba Business Overview Table 152. Horiba Hematological Cancers Product Table 153. Horiba Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 154. Horiba Recent Development Table 155. DiagnoCure Inc. Company Details Table 156. DiagnoCure Inc. Business Overview Table 157. DiagnoCure Inc. Hematological Cancers Product Table 158. DiagnoCure Inc. Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 159. DiagnoCure Inc. Recent Development Table 160. Astellas Pharma US Company Details Table 161. Astellas Pharma US Business Overview Table 162. Astellas Pharma US Hematological Cancers Product Table 163. Astellas Pharma US Revenue in Hematological Cancers Business (2016-2021) & (US$ Million) Table 164. Astellas Pharma US Recent Development Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Global Hematological Cancers Market Share by Type: 2020 VS 2027 Figure 2. Pharmacological Therapies Features Figure 3. Stem Cell Transplantation Features Figure 4. Surgery and Radiation Therapy Features Figure 5. Anemia Treatment Features Figure 6. Thrombosis Treatment Features Figure 7. Neutopenia Treatment Features Figure 8. Symptomatic treatment Features Figure 9. Global Hematological Cancers Market Share by Application: 2020 VS 2027 Figure 10. Epidemiology Case Studies Figure 11. Pathophysiology of Leukemic Stem Cells Case Studies Figure 12. Kidney Diseases Case Studies Figure 13. Genetic Diseases Case Studies Figure 14. Other Diseases Case Studies Figure 15. Hematological Cancers Report Years Considered Figure 16. Global Hematological Cancers Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 17. Global Hematological Cancers Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 18. Global Hematological Cancers Market Share by Regions: 2020 VS 2027 Figure 19. Global Hematological Cancers Market Share by Regions (2022-2027) Figure 20. Global Hematological Cancers Market Share by Players in 2020 Figure 21. Global Top Hematological Cancers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Cancers as of 2020 Figure 22. The Top 10 and 5 Players Market Share by Hematological Cancers Revenue in 2020 Figure 23. Global Hematological Cancers Revenue Market Share by Type (2016-2021) Figure 24. Global Hematological Cancers Revenue Market Share by Type (2022-2027) Figure 25. North America Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. North America Hematological Cancers Market Share by Type (2016-2027) Figure 27. North America Hematological Cancers Market Share by Application (2016-2027) Figure 28. North America Hematological Cancers Market Share by Country (2016-2027) Figure 29. United States Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Canada Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Europe Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Europe Hematological Cancers Market Share by Type (2016-2027) Figure 33. Europe Hematological Cancers Market Share by Application (2016-2027) Figure 34. Europe Hematological Cancers Market Share by Country (2016-2027) Figure 35. Germany Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. France Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. U.K. Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Italy Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Russia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Nordic Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Asia-Pacific Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Asia-Pacific Hematological Cancers Market Share by Type (2016-2027) Figure 43. Asia-Pacific Hematological Cancers Market Share by Application (2016-2027) Figure 44. Asia-Pacific Hematological Cancers Market Share by Region (2016-2027) Figure 45. China Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Japan Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. South Korea Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Southeast Asia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. India Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Australia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Latin America Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Latin America Hematological Cancers Market Share by Type (2016-2027) Figure 53. Latin America Hematological Cancers Market Share by Application (2016-2027) Figure 54. Latin America Hematological Cancers Market Share by Country (2016-2027) Figure 55. Mexico Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Brazil Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Middle East & Africa Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Middle East & Africa Hematological Cancers Market Share by Type (2016-2027) Figure 59. Middle East & Africa Hematological Cancers Market Share by Application (2016-2027) Figure 60. Middle East & Africa Hematological Cancers Market Share by Country (2016-2027) Figure 61. Turkey Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Saudi Arabia Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 63. UAE Hematological Cancers Market Size YoY Growth (2016-2027) & (US$ Million) Figure 64. Karyopharm Therapeutics Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 65. Johnson & Johnson Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 66. Roche Diagnostics A/S Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 67. AbbVie Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 68. Novartis Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 69. Kite Pharma Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 70. Celgene Corporation Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 71. Abbott Laboratories Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 72. Beckman Coulter Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 73. HemoCue AB Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 74. C. R. Bard Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 75. Siemens AG Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 76. Sysmex Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 77. Mindray Medical International Limited Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 78. Bio-Rad Laboratories Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 79. The Medicine Company Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 80. Pharmacyclics Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 81. Horiba Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 82. DiagnoCure Inc. Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 83. Astellas Pharma US Revenue Growth Rate in Hematological Cancers Business (2016-2021) Figure 84. Bottom-up and Top-down Approaches for This Report Figure 85. Data Triangulation Figure 86. Key Executives Interviewed

Karyopharm Therapeutics Johnson & Johnson Roche Diagnostics A/S AbbVie Novartis Kite Pharma Celgene Corporation Abbott Laboratories Beckman Coulter HemoCue AB C. R. Bard Siemens AG Sysmex Mindray Medical International Limited Bio-Rad Laboratories The Medicine Company Pharmacyclics Horiba DiagnoCure Inc. Astellas Pharma US